A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab
and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is
defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects
must not have received prior systemic therapy for advanced HCC in keeping with the first-line
setting of this study.
Phase:
Phase 2
Details
Lead Sponsor:
Muhammad Beg University of Texas Southwestern Medical Center